RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A DealsApril 8, 2024 - RBC Capital Markets - The M&A Pool Set to Accelerate Biotech Innovation - Transcript
https://www.rbccm.com/en/insights/transcripts/the-ma-pool-set-to-accelerate-biotech-innovation.page Alex Lim
I think the theme has been over the last six months to a year, really, you know, big pharma looking for late stage commercial assets to acquire from biotech. .... [And] you're seeing a lot of pharma companies do deals around this area to try to catch up to try to go at it with different mechanisms and modalities and, and so that's exciting to see. And I think that it impacts the whole ecosystem, because they're not just looking at near term kind of revenue, but they're looking at fundamental science and how it might actually impact the broader patient treatment experience over decades,
Tim Chung
And obviously a lot of excitement in M&A coming back in a more so in the sub $10 billion valuation range takeouts and you know, with, with strong M&A, generally strong capital markets as, as the beltex (inaudible) generally strong clinical data, there's more and more interest for large pharma to take out these companies and, and what that's going to be, you know, return on capital to these investors and, and obviously, redeployment back into the space, so, you know, M&A, and capital markets all working well, together is obviously great for the biotech markets.